Cryo Cell International Free Cash Flow (FCF) History (CCEL)
Cryo Cell International reported $5.2M in free cash flow for fiscal 2025, an increase of 45.49% from the previous fiscal year, with a free cash flow margin of 16.63%.
View full Cryo Cell International company overviewCryo Cell International free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-11-30 | $5.2M | $1.6M | +45.49% | +16.63% |
| 2024 | 2024-11-30 | $3.6M | $1.5M | +73.36% | +11.28% |
| 2023 | 2023-11-30 | $2.1M | $5.7M | — | +6.64% |
| 2022 | 2022-11-30 | −$3.6M | −$9.7M | — | −11.85% |
| 2021 | 2021-11-30 | $6.1M | −$2.3M | −27.19% | +21.09% |
| 2020 | 2020-11-30 | $8.4M | $2.7M | +48.54% | +26.86% |
| 2019 | 2019-11-30 | $5.6M | $745,381 | +15.25% | +17.70% |
| 2018 | 2018-11-30 | $4.9M | −$732,673 | −13.04% | +16.73% |
| 2017 | 2017-11-30 | $5.6M | $974,847 | +20.99% | +22.14% |
| 2016 | 2016-11-30 | $4.6M | −$97,989 | −2.07% | +20.08% |
| 2015 | 2015-11-30 | $4.7M | $3.3M | +230.68% | +22.49% |
| 2014 | 2014-11-30 | $1.4M | $962,108 | +203.75% | +7.13% |
| 2013 | 2013-11-30 | $472,196 | $244,833 | +107.68% | +2.49% |
| 2012 | 2012-11-30 | $227,363 | −$86,044 | −27.45% | +1.27% |
| 2011 | 2011-11-30 | $313,407 | −$1.6M | −83.84% | +1.75% |
| 2010 | 2010-11-30 | $1.9M | — | — | +10.92% |
Cryo Cell International quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $1.8M | $1.2M | +181.29% | +23.32% |
| Q1 2026 | 2026-02-28 | $584,762 | −$307,248 | −34.44% | +7.61% |
| Q4 2025 | 2025-11-30 | $1.2M | −$935,058 | −43.52% | +15.47% |
| Q3 2025 | 2025-08-31 | $2.5M | $246,333 | +10.94% | +31.92% |
| Q2 2025 | 2025-05-31 | $644,606 | $623,057 | +2891.35% | +8.13% |
| Q1 2025 | 2025-02-28 | $892,010 | $1.7M | — | +11.19% |
| Q4 2024 | 2024-11-30 | $2.1M | $519,244 | +31.87% | +26.78% |
| Q3 2024 | 2024-08-31 | $2.3M | $3.6M | — | +27.91% |
| Q2 2024 | 2024-05-31 | $21,549 | −$510,108 | −95.95% | +0.27% |
| Q1 2024 | 2024-02-29 | −$814,587 | −$2.1M | — | −10.37% |
| Q4 2023 | 2023-11-30 | $1.6M | −$775,324 | −32.24% | +20.69% |
| Q3 2023 | 2023-08-31 | −$1.3M | $7.2M | — | −17.14% |
| Q2 2023 | 2023-05-31 | $531,657 | −$1.1M | −67.59% | +6.84% |
| Q1 2023 | 2023-02-28 | $1.3M | $409,204 | +47.63% | +16.21% |
| Q4 2022 | 2022-11-30 | $2.4M | $1.0M | +73.32% | +30.97% |
| Q3 2022 | 2022-08-31 | −$8.5M | −$9.1M | — | −111.31% |
| Q2 2022 | 2022-05-31 | $1.6M | $113,426 | +7.43% | +21.49% |
| Q1 2022 | 2022-02-28 | $859,122 | −$1.8M | −67.58% | +11.84% |
| Q4 2021 | 2021-11-30 | $1.4M | −$1.5M | −52.63% | +18.97% |
| Q3 2021 | 2021-08-31 | $527,737 | −$1.5M | −74.26% | +7.03% |
| Q2 2021 | 2021-05-31 | $1.5M | $747,889 | +96.02% | +21.19% |
| Q1 2021 | 2021-02-28 | $2.7M | $41,462 | +1.59% | +38.63% |
| Q4 2020 | 2020-11-30 | $2.9M | $2.0M | +202.13% | +38.85% |
| Q3 2020 | 2020-08-31 | $2.0M | −$640,246 | −23.80% | +25.26% |
| Q2 2020 | 2020-05-31 | $778,925 | $611,030 | +363.94% | +9.90% |
| Q1 2020 | 2020-02-29 | $2.6M | $803,645 | +44.52% | +34.23% |
| Q4 2019 | 2019-11-30 | $969,495 | $163,373 | +20.27% | +12.16% |
| Q3 2019 | 2019-08-31 | $2.7M | $79,347 | +3.04% | +32.71% |
| Q2 2019 | 2019-05-31 | $167,895 | $135,863 | +424.15% | +2.07% |
| Q1 2019 | 2019-02-28 | $1.8M | $366,798 | +25.50% | +24.08% |
| Q4 2018 | 2018-11-30 | $806,122 | −$1.3M | −61.03% | +9.38% |
| Q3 2018 | 2018-08-31 | $2.6M | $1.4M | +122.51% | +33.17% |
| Q2 2018 | 2018-05-31 | $32,032 | −$1.9M | −98.36% | +0.49% |
| Q1 2018 | 2018-02-28 | $1.4M | $1.0M | +237.49% | +23.09% |
| Q4 2017 | 2017-11-30 | $2.1M | $994,719 | +92.64% | +31.95% |
| Q3 2017 | 2017-08-31 | $1.2M | $1.1M | +1559.75% | +17.01% |
| Q2 2017 | 2017-05-31 | $2.0M | $17,759 | +0.92% | +31.30% |
| Q1 2017 | 2017-02-28 | $426,138 | −$591,932 | −58.14% | +7.38% |
| Q3 2016 | 2016-08-31 | $1.1M | −$411,368 | −27.70% | +16.96% |
| Q1 2016 | 2016-02-29 | $70,694 | −$234,967 | −76.87% | +1.37% |
| Q4 2015 | 2015-11-30 | $1.9M | $1.0M | +107.97% | +33.36% |
| Q3 2015 | 2015-08-31 | $1.0M | $1.1M | — | +18.73% |
| Q2 2015 | 2015-05-31 | $1.5M | $1.6M | — | +29.62% |
| Q1 2015 | 2015-02-28 | $305,661 | $560,244 | — | +6.31% |
| Q3 2014 | 2014-08-31 | $930,033 | $499,388 | +115.96% | +18.83% |
| Q1 2014 | 2014-02-28 | −$117,721 | −$546,103 | — | −2.21% |
| Q4 2013 | 2013-11-30 | −$132,248 | −$449,413 | — | −2.81% |
| Q3 2013 | 2013-08-31 | −$254,583 | −$707,374 | — | −5.27% |
| Q2 2013 | 2013-05-31 | $430,645 | $1.1M | — | +8.86% |
| Q1 2013 | 2013-02-28 | $428,382 | $349,716 | +444.56% | +9.31% |
| Q4 2012 | 2012-11-30 | $317,165 | $12,513 | +4.11% | +6.58% |
| Q3 2012 | 2012-08-31 | $452,791 | $429,652 | +1856.83% | +9.97% |
| Q2 2012 | 2012-05-31 | −$629,539 | −$497,541 | — | −14.23% |
| Q1 2012 | 2012-02-29 | $78,666 | $70,510 | +864.52% | +1.88% |
| Q4 2011 | 2011-11-30 | $304,652 | — | — | +6.87% |
| Q3 2011 | 2011-08-31 | $23,139 | — | — | +0.52% |
| Q2 2011 | 2011-05-31 | −$131,998 | — | — | −2.87% |
| Q1 2011 | 2011-02-28 | $8,156 | — | — | +0.18% |
Cryo Cell International free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $8.4M to $5.2M, a compound annual decline of 8.91%. Cryo Cell International's latest reported quarter, Q2 2026, generated $1.8M in free cash flow, an increase of 181.29% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cryo Cell International filings at SEC.gov ↗